一种新型抗组胺药HC 20 - 511与赛庚啶（periactin）治疗慢性荨麻疹的比较。
Comparison of a new antihistamine HC 20-511 with cyproheptadine (Periactin) in chronic urticaria.
作者信息
Kuokkanen K
出版信息
Acta Allergol. 1977 Oct;32(5):316-20. doi: 10.1111/j.1398-9995.1977.tb02573.x.
Abstract
The effect and tolerance of a new antihistamine, HC 20-511, in daily doses of 2 and 4 mg was compared with cyproheptadine (Periactin) 8 mg daily in 50 cases of chronic urticaria. HC 20-511 4 mg daily proved to be the most effective, rapid and long-lasting. HC 20-511 had less sedative effect than cyproheptadine, but both possessed the same appetite-stimulating effect. However, this was not noted with the smaller dosage of HC 20-511.
摘要
将一种每日剂量为2毫克和4毫克的新型抗组胺药HC 20 - 511与每日8毫克的赛庚啶（periactin）在50例慢性荨麻疹患者中进行疗效和耐受性比较。结果证明，每日服用4毫克的HC 20 - 511效果最佳，起效迅速且作用持久。HC 20 - 511的镇静作用比赛庚啶小，但两者都有相同的刺激食欲的作用。然而，较小剂量的HC 20 - 511未观察到这种情况。
相似文献
1
Comparison of a new antihistamine HC 20-511 with cyproheptadine (Periactin) in chronic urticaria.一种新型抗组胺药HC 20 - 511与赛庚啶（periactin）治疗慢性荨麻疹的比较。
Acta Allergol. 1977 Oct;32(5):316-20. doi: 10.1111/j.1398-9995.1977.tb02573.x.
2
Comparison of the new antihistamine acrivastine (BW 825C) versus cyproheptadine in the treatment of idiopathic cold urticaria.
Dermatologica. 1988;177(2):98-103. doi: 10.1159/000248523.
3
Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria.氯雷他定（每日一次，每次10毫克）治疗特发性慢性荨麻疹的疗效与安全性。
J Am Acad Dermatol. 1988 Jul;19(1 Pt 1):138-9. doi: 10.1016/s0190-9622(88)80230-5.
4
H-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.H-抗组胺药对组胺和可待因诱发的风团的抑制作用不能预测慢性寒冷性荨麻疹的反应。
J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):2043-2044. doi: 10.1016/j.jaip.2019.01.030. Epub 2019 Jan 29.
5
6
The role of cyproheptadine in the treatment of cold urticaria.
J Allergy Clin Immunol. 1980 Apr;65(4):309-12. doi: 10.1016/0091-6749(80)90161-x.
7
Treatment of urticaria and angioedema: low-sedating H1-type antihistamines.荨麻疹和血管性水肿的治疗：低镇静作用的H1型抗组胺药。
J Am Acad Dermatol. 1991 Jun;24(6 Pt 2):1084-7. doi: 10.1016/0190-9622(91)70161-t.
8
Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study.每日一次服用卢帕他定可改善慢性特发性荨麻疹症状：一项随机、双盲、安慰剂对照研究。
Eur J Dermatol. 2007 May-Jun;17(3):223-8. doi: 10.1684/ejd.2007.0153. Epub 2007 May 4.
9
Terfenadine in chronic urticaria: a comparison with clemastine and placebo.特非那定治疗慢性荨麻疹：与氯马斯汀和安慰剂的比较。
Cutis. 1986 Aug;38(2):128-30.
10
Treatment of chronic idiopathic urticaria with combined H1 and H2 blockers.联合使用H1和H2受体阻滞剂治疗慢性特发性荨麻疹
Clin Allergy. 1978 Sep;8(5):429-33. doi: 10.1111/j.1365-2222.1978.tb01493.x.
引用本文的文献
1
Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review.食欲素药物赛庚啶的安全性。法国国家药物警戒数据库分析及系统评价
Front Pediatr. 2021 Sep 29;9:712413. doi: 10.3389/fped.2021.712413. eCollection 2021.
2
H1-antihistamines for chronic spontaneous urticaria.用于慢性自发性荨麻疹的H1抗组胺药。
Cochrane Database Syst Rev. 2014 Nov 14;2014(11):CD006137. doi: 10.1002/14651858.CD006137.pub2.
3
Ketotifen in the management of chronic urticaria: resurrection of an old drug.酮替芬在慢性荨麻疹治疗中的应用：一种老药的复兴
Ann Allergy Asthma Immunol. 2013 Dec;111(6):433-6. doi: 10.1016/j.anai.2013.10.003. Epub 2013 Oct 25.
Zotero 插件